Persistent migraine aura in an adolescent girl.

A 14-year-old girl presented with a prolonged migraine visual aura of several weeks' duration. Symptoms gradually resolved over a 6-week period, with no recurrence of visual aura over a 20-month follow-up period. Although there is significant overlap between the features of stereotypical and persistent migraine auras, or "visual snow," the latter tend to be unformed and can occupy the entire visual field of both eyes. To our knowledge, this phenomenon has been reported only twice before in children. Recognition of its features will allow the pediatric ophthalmologist to differentiate persistent visual aura from visual hallucinations.

Baseline Factors Predictive of SLT Response: A Prospective Study.

Purpose. To study the response to Selective Laser Trabeculoplasty (SLT) according to baseline medical treatment, angle pigmentation, age, diagnosis (open-angle glaucoma or ocular hypertension), and baseline intraocular pressure (IOP). Methods. 74 eyes of 74 patients were enrolled in this study. Baseline characteristics were recorded for each patient. IOP in the treated and fellow eyes was measured at baseline, and 1 month, 6 months, and 12 months following SLT. IOP changes in the different groups were compared using two-way ANOVA and Pearson's correlation. Results. The mean age of our cohort was 71 ± 10 years. The mean baseline IOP was 21.5 ± 5 mmHg, and the mean change in IOP from baseline in the treated eye at one year was -4.67 ± 3.40 mmHg. Higher baseline IOP was highly correlated with greater absolute IOP decrease. Prostaglandin analogue use at baseline was shown to be associated with a statistically decreased IOP-lowering response following SLT when corrected for baseline IOP. No significant differences in IOP response were found when comparing groups stratified for age, angle pigmentation, phakic status, gender, or diagnosis. Discussion. The results of this study confirm the finding that higher baseline IOP is a predictor of greater IOP response following SLT, and that pretreatment with prostaglandin analogue therapy is associated with a decreased IOP-lowering response following SLT. The study is limited by the small number of eyes with data available for complete case analysis.

Reducing wait time for cataract surgery: comparison of 2 historical cohorts of patients in Montreal.

OBJECTIVE: A cataract efficiency program was implemented in Montreal in 2003 to decrease surgery wait time. Our goal was to determine whether health, adverse events during wait time, and outcome of patients presenting for cataract surgery differed from 1999 to 2006 in Montreal. DESIGN: Prospective preoperative and postoperative observational study performed at 2 time points 6 years apart. PARTICIPANTS: Patients awaiting first-eye cataract surgery at Maisonneuve-Rosemont Hospital: 509 patients in 1999-2000 and 206 patients in 2006-2007. METHODS: Patients awaiting first-eye cataract surgery were recruited from Maisonneuve-Rosemont Hospital in 1999-2000 (n = 509) and a second cohort was recruited in 2006-2007 (n = 206). Date of entry onto the hospital waiting list and date of cataract surgery were recorded. About 2 weeks before surgery, patients were asked about accidents and falls while waiting, visual difficulty, and satisfaction with vision and wait time. Visual acuity was measured in each eye. Patients also completed interviewer-administered questionnaires: the 5-item Cataract Symptom Scale, Visual Function-14 Questionnaire (VF-14), Short Form Health Survey-36, Geriatric Depression Scale, and the 14-item Systemic Comorbidity Scale. The interview was repeated after surgery. RESULTS: In 1999, 39% of patients waited more than 6 months for cataract surgery, and this was reduced to 29% in 2006. Patients had better preoperative visual acuity in the surgical eye, less visual difficulty, and fewer cataract symptoms, and reported fewer accidents while waiting for surgery in 2006. The change in visual acuity after surgery was nonetheless the same in the 2 cohorts. The 2006 cohort achieved significantly higher VF-14 scores and reported more satisfaction with vision after surgery than did the 1999 cohort. CONCLUSIONS: Patients had cataract surgery sooner in the disease process in 2006-2007 compared with 1999-2000, with changes in visual acuity after surgery that were clinically significant in both cohorts.

Cataract-related vision loss and depression in a cohort of patients awaiting cataract surgery.

OBJECTIVE: As provinces consider what an acceptable cataract surgery wait time should be, research is needed on the risk of adverse events, such as depression, while waiting for care. We sought to determine whether worse visual acuity is related to depressive symptoms in patients waiting to have cataract surgery. DESIGN: Cohort study. PARTICIPANTS: Six hundred seventy-two patients awaiting cataract surgery were recruited from Maisonneuve-Rosemont Hospital in Montreal, Que. METHODS: About 2 weeks before surgery and 4 months after surgery, patients completed the Visual Function-14 questionnaire, a measure of the self-report of difficulty performing visual tasks, and the 30-item Geriatric Depression Scale. Patients were also asked about systemic and ocular comorbidities. Visual acuity was measured with pinhole correction. Date of entry onto the hospital waiting list and date of cataract surgery were recorded. RESULTS: Forty-one percent of patients had visual acuity of 6/18 or worse in the surgical eye, whereas 26% showed signs of depression before surgery (Geriatric Depression Scale-30 > or = 10). In a logistic regression model, those with visual acuity < or = 6/18 in their surgical eye had a 59% higher adjusted odds of depression (odds ratio 1.59, 95% CI 1.09-2.33). There was statistically significant evidence that the relationship between visual acuity and depression was mediated by greater reported difficulty on the Visual Function-14 (p < 0.05). CONCLUSIONS: Patients with worse visual acuity were more likely to be depressed while waiting for cataract surgery. Shortening the wait time for cataract surgery, especially for those with worse vision, could potentially reduce the risk or shorten the duration of depression.

Short-term intraocular pressure changes after intravitreal injection of bevacizumab.

BACKGROUND: This study examines the changes in short-term intraocular pressure (IOP) in patients receiving intravitreally administered bevacizumab. A prospective series of consecutive patients undergoing injection of intravitreal bevacizumab was investigated. METHODS: All patients received bevacizumab (0.05 cc) injected intravitreally in a standard fashion. IOP was measured at baseline, 2, 5, and 30 minutes after injection by 1 of 2 observers using Goldman applanation tonometry. An intraobserver study was done to assess agreement in IOP measurements. RESULTS: We accrued 104 patients with a mean age of 76 years: 58% were female, and 42% were male. Most patients (85%) were being treated for neovascular age-related macular degeneration. The mean IOP values at baseline, 2, 5, and 30 minutes after injection were 14.0 (95% confidence interval [CI] 13.4-14.7) mm Hg, 36.1 (95% CI 33.5-38.6) mm Hg, 25.7 (95% CI 23.8-27.5) mm Hg, and 15.5 (95% CI 12.4-16.51) mm Hg, respectively. Three patients (2.9%) had an IOP of 25 mm Hg or higher at 30 minutes. IOP normalized within 2 hours without medical therapy in 2 of these patients, and 1 patient required a 1-week course of glaucoma medication. Regression analysis showed a trend towards phakic patients having higher IOP at 30 minutes (odds ratio = 3.2; p = 0.089). INTERPRETATION: Intravitreal injection of bevacizumab is safe with respect to short-term IOP changes, as almost all patients' IOP returned to a safe range (<25 mm Hg) within 30 minutes. Elevated IOP at 30 minutes after injection does occur, rarely, thus clinicians should consider checking IOP after injection as a precaution. Transient extreme IOP elevations occur in a significant percentage of patients, but the consequences of these events are unknown.